Physician profile
Augusto Parra
NPI 1679588198
$2,392.20
in general payments reported to CMS, 2019-2025
9 companies · $389 in 2025
The $389 reported for 2025 was more than what 81% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $186 · 2021: $135 · 2022: $250 · 2023: $263 · 2024: $810 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $483.65 | 2019-2020 | |
| Ucb, INC. | $440.93 | 2024-2025 | Briviact |
| Btg International INC. | $403.10 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $385.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $237.07 | 2023-2024 | Andexxa |
| Chiesi USA, INC. | $192.17 | 2024 | Cleviprex |
| Abbott Laboratories | $143.70 | 2023 | Cardiomems |
| Zoll Medical Corporation | $61.21 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $44.78 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augusto Parra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.